Publication: Cancer Chemotherapy and Pharmacology
Abstract
Imatinib is the first-line treatment for chronic myeloid leukemia (CML), but real-world population pharmacokinetic data to support individualized dosing in Chinese patients were limited. This study enrolled 230 CML patients, using 424 steady-state concentration measurements to build a population pharmacokinetic model and Monte Carlo simulations with Phoenix NLME, examining demographic, biological, and pharmacogenetic covariates including ten single nucleotide polymorphisms. Hemoglobin level and estimated glomerular filtration rate were identified as significant covariates for imatinib clearance, while none of the tested genetic polymorphisms showed a significant effect. The findings suggest caution is warranted when treating CML patients with moderate-to-severe renal impairment or significant hemoglobin changes, given their effect on imatinib exposure.
Author(s): He S, Shao Q, Zhao J, Bian J, Zhao Y, Hao X, Li Y, Hu L, Liu B, He H, Huang L, Jiang Q
Published: 2023 年 8 月 25 日
Phoenix NLME：Real-World Population Modeling
Phoenix NLME built a real-world population PK model from over 200 CML patients in this study, flagging renal and hemoglobin factors that shift drug exposure. Phoenix NLME can be paired with Model Designer to select, configure, and simulate models directly in the browser, guided by an AI assistant, within a Phoenix platform designed to move teams from data to decision in a fraction of the time.
